In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
A series of 6-benzyl-1,3-benzodioxoles have been synthesized and evaluated against the in vivo ip P388 murine lymphocytic leukemia. Selected activities against this system were tested against the additional in vivo systems L1210, B16, M5076, and MX1. The most active of the 6-benzyl-1,3-benzodioxoles tested were as effective as podophyllotoxin as experimental antitumor agents in vivo, but larger doses were required. Three of the P388-active series members were active against the in vitro astrocytoma assay, which detects compounds that interfere with or bind to tubulin.
Jurd
L
L
Developmental Therapeutics Program, National Cancer Institute, Bethesda, Maryland 20892.
Narayanan
V L
VL
Paull
K D
KD
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy; D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004149:Dioxoles / Q000138:chemical synthesis* / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D014404:Tubulin / Q000378:metabolism
D000970:Antineoplastic Agents; D004149:Dioxoles; D014404:Tubulin; D003994:Bucladesine; D004264:DNA Topoisomerases, Type I